MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- GLENMARK LIFE SCIENCES - SYNCOM FORMULATIONS
GLENMARK LIFE SCIENCES vs SYNCOM FORMULATIONS - Comparison Results
Current Valuations
| GLENMARK LIFE SCIENCES | SYNCOM FORMULATIONS | GLENMARK LIFE SCIENCES/ SYNCOM FORMULATIONS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.9 | 44.9 | 42.2% | View Chart |
| P/BV | x | 4.6 | 4.6 | 99.8% | View Chart |
| Dividend Yield | % | 2.6 | 0.0 | - |
Financials
 GLENMARK LIFE SCIENCES  SYNCOM FORMULATIONS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GLENMARK LIFE SCIENCES Mar-23 |
SYNCOM FORMULATIONS Mar-23 |
GLENMARK LIFE SCIENCES/ SYNCOM FORMULATIONS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 534 | 13 | 4,107.7% | |
| Low | Rs | 369 | 5 | 8,109.9% | |
| Sales per share (Unadj.) | Rs | 176.4 | 2.4 | 7,393.4% | |
| Earnings per share (Unadj.) | Rs | 38.1 | 0.2 | 17,848.3% | |
| Cash flow per share (Unadj.) | Rs | 41.5 | 0.3 | 15,868.6% | |
| Dividends per share (Unadj.) | Rs | 21.00 | 0 | - | |
| Avg Dividend yield | % | 4.7 | 0 | - | |
| Book value per share (Unadj.) | Rs | 174.0 | 2.7 | 6,387.2% | |
| Shares outstanding (eoy) | m | 122.53 | 940.00 | 13.0% | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 2.6 | 3.7 | 69.6% | |
| Avg P/E ratio | x | 11.8 | 41.1 | 28.8% | |
| P/CF ratio (eoy) | x | 10.9 | 33.5 | 32.4% | |
| Price / Book Value ratio | x | 2.6 | 3.2 | 80.6% | |
| Dividend payout | % | 55.1 | 0 | - | |
| Avg Mkt Cap | Rs m | 55,321 | 8,249 | 670.7% | |
| No. of employees | `000 | NA | NA | - | |
| Total wages/salary | Rs m | 1,802 | 244 | 737.3% | |
| Avg. sales/employee | Rs Th | 0 | 0 | - | |
| Avg. wages/employee | Rs Th | 0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 0 | 0 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 21,612 | 2,243 | 963.7% | |
| Other income | Rs m | 290 | 146 | 198.3% | |
| Total revenues | Rs m | 21,902 | 2,389 | 917.0% | |
| Gross profit | Rs m | 6,423 | 199 | 3,225.5% | |
| Depreciation | Rs m | 421 | 45 | 927.4% | |
| Interest | Rs m | 5 | 34 | 16.1% | |
| Profit before tax | Rs m | 6,286 | 266 | 2,365.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,616 | 65 | 2,486.1% | |
| Profit after tax | Rs m | 4,670 | 201 | 2,326.5% | |
| Gross profit margin | % | 29.7 | 8.9 | 334.7% | |
| Effective tax rate | % | 25.7 | 24.5 | 105.1% | |
| Net profit margin | % | 21.6 | 8.9 | 241.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,687 | 1,817 | 1,303.7% | |
| Current liabilities | Rs m | 10,228 | 1,132 | 903.8% | |
| Net working cap to sales | % | 62.3 | 30.6 | 203.8% | |
| Current ratio | x | 2.3 | 1.6 | 144.2% | |
| Inventory Days | Days | 2 | 231 | 0.7% | |
| Debtors Days | Days | 136 | 1,229 | 11.1% | |
| Net fixed assets | Rs m | 8,518 | 1,961 | 434.3% | |
| Share capital | Rs m | 245 | 940 | 26.1% | |
| "Free" reserves | Rs m | 21,070 | 1,620 | 1,300.5% | |
| Net worth | Rs m | 21,315 | 2,560 | 832.6% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 32,205 | 3,778 | 852.4% | |
| Interest coverage | x | 1,150.2 | 8.8 | 13,050.7% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 0.6 | 113.1% | |
| Return on assets | % | 14.5 | 6.2 | 233.7% | |
| Return on equity | % | 21.9 | 7.8 | 279.4% | |
| Return on capital | % | 29.5 | 11.7 | 252.1% | |
| Exports to sales | % | 0 | 63.3 | 0.0% | |
| Imports to sales | % | 0 | 7.7 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,419 | 0.0% | |
| Imports (cif) | Rs m | NA | 172 | 0.0% | |
| Fx inflow | Rs m | 9,691 | 1,419 | 682.9% | |
| Fx outflow | Rs m | 5,001 | 204 | 2,446.4% | |
| Net fx | Rs m | 4,689 | 1,215 | 386.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,134 | 105 | 2,976.6% | |
| From Investments | Rs m | -1,541 | -450 | 342.9% | |
| From Financial Activity | Rs m | -3,876 | 350 | -1,107.4% | |
| Net Cashflow | Rs m | -2,283 | 6 | -39,504.2% | |
Share Holding
| Indian Promoters | % | 82.9 | 50.6 | 163.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.3 | 0.1 | 6,637.5% | |
| FIIs | % | 4.6 | 0.1 | 5,712.5% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.2 | 49.4 | 34.7% | |
| Shareholders | 185,531 | 325,761 | 57.0% | ||
| Pledged promoter(s) holding | % | 9.5 | 0.0 | - |
Compare GLENMARK LIFE SCIENCES With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
More on GLENMARK LIFE SCIENCES vs SYNCOM FORMULATIONS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
GLENMARK LIFE SCIENCES vs SYNCOM FORMULATIONS Share Price Performance
| Period | GLENMARK LIFE SCIENCES | SYNCOM FORMULATIONS | S&P BSE HEALTHCARE |
|---|---|---|---|
| 1-Day | 0.41% | -0.79% | -0.44% |
| 1-Month | 10.36% | 5.36% | 2.15% |
| 1-Year | 85.72% | 105.38% | 49.82% |
| 3-Year CAGR | 2.36% | 43.17% | 14.21% |
| 5-Year CAGR | 1.41% | 64.35% | 19.19% |
* Compound Annual Growth Rate
Here are more details on the GLENMARK LIFE SCIENCES share price and the SYNCOM FORMULATIONS share price.
Moving on to shareholding structures...
The promoters of GLENMARK LIFE SCIENCES hold a 82.9% stake in the company. In case of SYNCOM FORMULATIONS the stake stands at 50.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GLENMARK LIFE SCIENCES and the shareholding pattern of SYNCOM FORMULATIONS.
Finally, a word on dividends...
In the most recent financial year, GLENMARK LIFE SCIENCES paid a dividend of Rs 21.0 per share. This amounted to a Dividend Payout ratio of 55.1%.
SYNCOM FORMULATIONS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of GLENMARK LIFE SCIENCES, and the dividend history of SYNCOM FORMULATIONS.
For a sector overview, read our pharmaceuticals sector report.
Today's Market
![Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising]()
Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising(Closing)
After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.